Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 mezagitamab trial in primary IgA nephropathy
jRCT2031250228Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of mezagitamab in IgA nephropathy (IgAN) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in proteinuria at Week 36. Started Jul 2025; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031250228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250228.